The ANP32B Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung adenocarcinoma cell line. These cells harbor a targeted disruption of the ANP32B gene, creating a loss-of-function model for studying ANP32B-dependent mechanisms. The polyclonal format preserves editing heterogeneity, minimizing clonal selection biases and enhancing the representation of knockout phenotypes. Supplied as a validated cell population with confirmed ANP32B protein depletion, this product is an essential resource for apoptosis, chromatin dynamics, and cancer signaling investigations.
The parental A-549 cell line is a KRAS-mutant human lung adenocarcinoma epithelial model, established from a 58-year-old male. These cells form polarized monolayers and serve as a standard system for respiratory epithelial barrier analysis and cancer biology research. The activating KRAS mutation recapitulates a frequent oncogenic lesion in non-small cell lung cancer, making the cell line well-suited for investigating tumor cell survival, drug resistance, and DNA damage signaling. This genetic background provides a clinically relevant platform for interrogating ANP32B function within an oncogenic context.
ANP32B is a histone chaperone and endogenous inhibitor of protein phosphatase 2A (PP2A), regulating chromatin dynamics, histone acetylation, and mRNA export. It forms part of the SET complex with SET (TAF-I??), APE1, and NM23-H1 to coordinate DNA repair and apoptosis. Caspase-3 cleaves ANP32B during apoptosis, disrupting the SET complex, derepressing PP2A, and promoting apoptosome formation. Upstream regulators include protein kinase C (PKC) and DNA damage signals; downstream targets encompass PP2A, histone H3, and the apoptotic machinery. Loss of ANP32B removes this nodal integrator, enabling dissection of its role in chromatin biology and cell survival.
Within the KRAS-mutant A-549 background, ANP32B knockout permits systematic investigation of how chromatin regulation and apoptosis are co-opted by oncogenic signals. Disruption of ANP32B relieves PP2A inhibition, likely altering phosphorylation of histone H3 and other targets, while simultaneously compromising the SET complex??s DNA repair functions. These polyclonal cells thus serve as a model for exploring the contribution of ANP32B to lung adenocarcinoma cell survival, drug resistance, and stress adaptation. The knockout also facilitates examination of mRNA export dynamics and epigenetic reprogramming in a cancer-relevant context.
Researchers can employ these ANP32B knockout A-549 polyclonal cells in diverse experimental modalities, including Western blotting, RT-qPCR, immunofluorescence, and flow cytometry-based apoptosis assays. Caspase activity assays and PP2A phosphatase measurements offer direct functional readouts of the knockout??s impact on apoptotic signaling and phosphatase regulation. Chromatin immunoprecipitation coupled with qPCR (ChIP-qPCR) enables profiling of histone H3 modifications, while cell viability and clonogenic survival assays provide insight into chemosensitivity and proliferative capacity. The model supports investigations of DNA repair kinetics, SET complex assembly, and mRNA export pathways. For additional information, please contact Ascent Research.
